Author:
Stella Peter,Gold-von Simson Gabrielle
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Genetics(clinical),General Medicine
Reference11 articles.
1. Pharmaceuticals in the USA: ISIC 2423. 2012, Euromonitor International, Chicago, IL
2. Sticker Shock: Will Orphan Drug Reimbursement Remain Stable? Forbes at , [ http://www.forbes.com/sites/edsilverman/2013/10/09/sticker-shock-will-orphan-drug-reimbursement-remain-stable/ ]
3. O’Sullivan BP, Orenstein DM, Milla CE: Pricing for orphan drugs: Will the market bear what society cannot?. JAMA. 2013, 310: 1343-1344. 10.1001/jama.2013.278129.
4. Abboud C, Berman E, Cohen A, Cortes J, DeAngelo D, Deininger M, Devine S, Druker B, Fathi A, Jabbour E, Jagasia M, Kantarjian H, Khoury J, Laneuville P, Larson R, Lipton J, Moore JO, Mughal T, O’Brien S, Pinilla-Ibarz J, Quintas-Cardama A, Radich J, Reddy V, Schiffer C, Shah N, Shami P, Silver RT, Snyder D, Stone R, Talpaz M, et al: The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts. Blood. 2013, 121: 4439-4442. 10.1182/blood-2013-03-490003.
5. Cohen J, Milne CP: Is the increasing cost of treating rare diseases sustainable?. Expert Opin Orphan Drugs. 2013, 1: 581-583. 10.1517/21678707.2013.819289.
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献